Erlotinib Linked to Deaths in Patients With Hepatic Impairment…
- This topic has 0 replies, 1 voice, and was last updated 16 years ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Erlotinib Linked to Deaths in Patients With Hepatic Impairment, Advanced Solid Tumours
OTTAWA, Ontario — December 17, 2008 — Hoffmann-La Roche Limited, in consultation with Health Canada, is informing healthcare professionals of important new safety information regarding the use of erlotinib (Tarceva) in patients with moderate hepatic impairment and advanced solid tumours.
Based on review of a pharmacokinetic study in patients with advanced solid tumours comparing patients with moderate hepatic impairment (Child-Pugh Score 7-9) and those with normal hepatic function:
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.